Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
207 stopped studies mapped to Malignant Cervical Neoplasm and descendants · 84% state a reason
Over the 207 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT04254107 | A Safety Study of SEA-TGT (SGN-TGT) in Advanced Cancer | Phase 1 | terminated | Feb 5, 2020 | Seagen Inc. | Study closed due to portfolio prioritization | Sponsor / business decision |
| NCT04665921 | A Study of SGN-STNV in Advanced Solid Tumors | Phase 1 | terminated | Dec 14, 2020 | Seagen Inc. | Study closed due to portfolio prioritization | Sponsor / business decision |
| NCT06752135 | Node Positive Cervical Cancer Treated by Neoadjuvant Chemotherapy Plus Radical Surgery: a…(HRCC1) | — | terminated | Dec 30, 2024 | Azienda Policlinico Umberto I | Retrospectively data collection complited | Other (stated, no rule matched) |
| NCT05500508 | Oral AMXT 1501 Dicaprate in Combination With IV DFMO | Phase 1 / Phase 2 | terminated | Aug 15, 2022 | Aminex Therapeutics, Inc. | Required re-formulation of DFMO from IV to capsule to maintain safety | Safety / toxicity |
| NCT06034860 | Study of MT-8421 as Monotherapy and in Combination With Nivolumab in Patients With… | Phase 1 | terminated | Sep 13, 2023 | Molecular Templates, Inc. | Sponsor Termination | Other (stated, no rule matched) |
| NCT05012397 | Milademetan in Advanced/Metastatic Solid Tumors | Phase 2 | terminated | Aug 19, 2021 | Rain Oncology Inc | Sponsor Decision | Sponsor / business decision |
| NCT03677024 | Evaluation of the Efficacy for Sentinel Lymph Node Policy in Intermediate-risk… | N/A | withdrawn | Sep 19, 2018 | Fudan University | This study was not approved by the Ethics Committee | Other (stated, no rule matched) |
| NCT06099418 | Efficacy and Safety of VB10.16 Alone or in Combination With Atezolizumab in Patients With… | Phase 2 | withdrawn | Oct 25, 2023 | Nykode Therapeutics ASA | Trial VB-C-04 was stopped due to company strategic reasons and recent changes in standard of care… | Sponsor / business decision |
| NCT03644342 | Study of Niraparib With Radiotherapy for Treatment of Metastatic Invasive Carcinoma of…(NIVIX) | Phase 1 / Phase 2 | terminated | Aug 23, 2018 | Michelle S Ludwig | A recent change in treatment landscape may make study futile | Other (stated, no rule matched) |
| NCT05001282 | A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor… | Phase 1 / Phase 2 | terminated | Aug 11, 2021 | Elucida Oncology | Lack of Funding - no safety issue with Drug; Company Permanently Closed | Safety / toxicity |
| NCT03439085 | DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine INO-3112 and… | Phase 2 | terminated | Feb 20, 2018 | M.D. Anderson Cancer Center | Project delays | Other (stated, no rule matched) |
| NCT03367871 | Combination Pembrolizumab, Chemotherapy and Bevacizumab in Patients With Cervical Cancer | Phase 2 | terminated | Dec 11, 2017 | University of Miami | Investigator left institution | Investigator |
| NCT05107739 | A Study of DeTIL-0255 in Adults With Advanced Malignancies | Phase 1 | terminated | Nov 4, 2021 | Nurix Therapeutics, Inc. | Sponsor Decision | Sponsor / business decision |
| NCT05033132 | A Phase II Study of Balstilimab Independently or in Combination With Zalifrelimab in… | Phase 2 | withdrawn | Sep 2, 2021 | Agenus Inc. | Study was never initiated. | Other (stated, no rule matched) |
| NCT02574442 | Pilot Study In Vivo Confocal Microscopy Probe for Cervical Precancer(Confocal) | — | terminated | Oct 12, 2015 | British Columbia Cancer Agency | Funding has run out | Funding |
| NCT03285841 | OCT-AF Imaging of Pre-cancers of Vulva and Cervix | — | terminated | Sep 18, 2017 | British Columbia Cancer Agency | No funding | Funding |
| NCT02923739 | Paclitaxel and Bevacizumab With or Without Emactuzumab in Treating Patients With… | Phase 2 | terminated | Oct 5, 2016 | M.D. Anderson Cancer Center | The study was terminated early by the Sponsor | Other (stated, no rule matched) |
| NCT03345784 | Testing AZD1775 inC Combination With Radiotherapy and Chemotherapy in Cervical, Upper… | Phase 1 | terminated | Nov 17, 2017 | National Cancer Institute (NCI) | Inadequate accrual rate | Enrollment / accrual |
| NCT04864782 | QL1604 Plus Chemotherapy in Subjects With Stage IVB, Recurrent, or Metastatic Cervical… | Phase 2 / Phase 3 | terminated | Apr 29, 2021 | Qilu Pharmaceutical Co., Ltd. | Phase 2 completed, phase 3 sponsor decided to terminate | Sponsor / business decision |
| NCT04187872 | LITT and Pembrolizumab in Recurrent Brain Metastasis(TORCH) | Phase 1 | terminated | Dec 5, 2019 | University of Florida | Sponsor terminated | Other (stated, no rule matched) |
| NCT03641287 | The Effects of Exercise on Distress, Quality of Life, and Biomarkers in Ovarian Cancer… | N/A | terminated | Aug 22, 2018 | University of Washington | Enrollment ended early due to the funding timeline | Enrollment / accrual |
| NCT05998941 | A Trial of TQB2868 Plus Platinum-based Chemotherapy With or Without Bevacizumab in the… | Phase 2 | withdrawn | Aug 21, 2023 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Slow progress in development, the sponsor decided to withdraw and no longer proceed. | Sponsor / business decision |
| NCT00745134 | Radiation Therapy and Capecitabine With or Without Curcumin Before Surgery in Treating… | Phase 2 | terminated | Sep 3, 2008 | M.D. Anderson Cancer Center | The trial was stopped early because there was only one patient with pCR among the first 15 patients… | Other (stated, no rule matched) |
| NCT05295589 | Comparing Standard of Care Chemotherapy Treatment to the Combination of Copanlisib and… | Phase 2 | withdrawn | Mar 25, 2022 | National Cancer Institute (NCI) | Drug supply issues | Drug supply |
| NCT04106167 | Long-term, Non-interventional, Observational Study Following Treatment With Fate… | — | terminated | Sep 26, 2019 | Fate Therapeutics | This study was terminated by the Sponsor. | Other (stated, no rule matched) |
| NCT01076400 | A Study of Adavosertib (MK-1775) in Combination With Topotecan/Cisplatin in Participants… | Phase 1 / Phase 2 | terminated | Feb 26, 2010 | Merck Sharp & Dohme LLC | The sponsor permanently suspended new enrollment into the trial and discontinued the study; which… | Safety / toxicity |
| NCT00794339 | Phase II Trial of 64Cu-ATSM PET/CT in Cervical Cancer(ACRIN6682) | Phase 2 | terminated | Nov 20, 2008 | American College of Radiology | transfer of funding | Funding |
| NCT04066894 | Sacral Nerve Stimulation in Treating Low Anterior Resection Syndrome or Fecal… | Phase 2 | terminated | Aug 26, 2019 | M.D. Anderson Cancer Center | Due to Issues Enrolling Patients | Enrollment / accrual |
| NCT05584332 | A Phase Ⅲ Study to Evaluate the Efficacy, Immunogenicity, Safety of Quadrivalent HPV… | Phase 3 | terminated | Oct 18, 2022 | Shanghai Bovax Biotechnology Co., Ltd. | Strategic adjustment | Sponsor / business decision |
| NCT00298064 | Assessment of EGFR Genomic Alterations as Prognostic Markers in Cervical Cancer | N/A | withdrawn | Mar 1, 2006 | University of New Mexico | not stated | Not stated |
| NCT05614453 | Tislelizumab in Combination With Sitravatinib for Recurrent/Metastatic Cervical Cancer…(ITTACC) | Phase 2 | withdrawn | Nov 14, 2022 | Australia New Zealand Gynaecological Oncology Group | BeiGene has withdrawn their support owing to sitravatinib supply concerns. Mirati is ceasing… | Drug supply |
| NCT01992861 | MRI and PET Imaging in Predicting Treatment Response in Patients With Stage IB-IVA… | — | terminated | Nov 25, 2013 | University of Washington | not stated | Not stated |
| NCT03824704 | A Study to Evaluate Rucaparib in Combination With Nivolumab in Patients With Selected… | Phase 2 | terminated | Jan 31, 2019 | pharmaand GmbH | Sponsor made a business decision to discontinue the study due to low accrual. | Enrollment / accrual |
| NCT02291055 | A Study of ADXS11-001 or MEDI4736 Alone or Combination In Cervical or Human… | Phase 1 / Phase 2 | terminated | Nov 14, 2014 | Advaxis, Inc. | not stated | Not stated |
| NCT02853604 | Study of ADXS11-001 in Participants With High Risk Locally Advanced Cervical Cancer(AIM2CERV) | Phase 3 | terminated | Aug 3, 2016 | Advaxis, Inc. | not stated | Not stated |
| NCT05506800 | Guangzhou Women's Health Cohort Study (GWHCS) | — | suspended | Aug 18, 2022 | Guangzhou Women and Children's Medical Center | Due to the rebound of the COVID-19 epidemic in the city, we have to suspend the project temporarily. | COVID-19 / pandemic |
| NCT05393635 | ITIL-168 in Advanced Solid Tumors(DELTA-2) | Phase 1 | withdrawn | May 26, 2022 | Instil Bio | business decision | Sponsor / business decision |
| NCT04672980 | RTX-321 Monotherapy in Patients With HPV 16+ Tumors | Phase 1 | terminated | Dec 17, 2020 | Rubius Therapeutics | The Sponsor terminated study after dosing 3 dose groups (9 pts) and closed trial on 11/30/22.… | Other (stated, no rule matched) |
| NCT04294836 | Curcumin in Advanced Cervical Cancer | Phase 2 | withdrawn | Mar 4, 2020 | Instituto Nacional de Cancerologia, Columbia | Issues with local regulatory authority | Other (stated, no rule matched) |
| NCT04762225 | RPTR-168 in Patients With Human Papillomavirus Strain 16 (HPV-16) E6/E7 Positive Tumors… | Phase 1 | terminated | Feb 21, 2021 | Repertoire Immune Medicines | Development program terminated | Other (stated, no rule matched) |
| NCT05061940 | This SCR-103 Protocol Will Permit Sites to Proactively Assess TAA, HLA and HPV-16 Status… | — | terminated | Sep 30, 2021 | Repertoire Immune Medicines | Development program terminated | Other (stated, no rule matched) |
| NCT03693846 | Nivolumab and Ipilimumab in Mucinous Colorectal and Appendiceal Tumors | Phase 2 | terminated | Oct 3, 2018 | Abramson Cancer Center at Penn Medicine | Terminated due to slow enrollment and lack of efficacy | Efficacy / futility |
| NCT04368130 | SIGNAL:Identifying Behavioral Anomalies Using Smartphones to Improve Cancer Care(SIGNAL) | N/A | withdrawn | Apr 29, 2020 | Dana-Farber Cancer Institute | The anomaly detection system is still under development and is not ready to test. | Other (stated, no rule matched) |
| NCT04943627 | Balstilimab Versus Investigator Choice Chemotherapy in Patients With Recurrent Cervical… | Phase 3 | withdrawn | Jun 29, 2021 | Agenus Inc. | Strategic Business Decision | Sponsor / business decision |
| NCT03834571 | Testing the Addition of Paclitaxel and Carboplatin Given After Standard Chemotherapy and… | Phase 2 | withdrawn | Feb 8, 2019 | AIDS Malignancy Consortium | Not approved by CTEP | Other (stated, no rule matched) |
| NCT04230954 | Cabozantinib Plus Pembrolizumab for Recurrent, Persistent and/or Metastatic Cervical… | Phase 2 | terminated | Jan 18, 2020 | University of South Alabama | PI left institution | Investigator |
| NCT04806945 | A Phase III Study to Evaluate Efficacy and Safety of First-Line Treatment With HLX10 +… | Phase 3 | withdrawn | Mar 19, 2021 | Shanghai Henlius Biotech | The sponsor terminated the trial. | Other (stated, no rule matched) |
| NCT03924245 | Olaparib and Entinostat in Patients With Recurrent, Platinum-Refractory, Resistant… | Phase 1 | terminated | Apr 23, 2019 | Vanderbilt-Ingram Cancer Center | Change in participant landscape and other treatment availability | Other (stated, no rule matched) |
| NCT03977311 | MR-Guided High-Intensity Focused Ultrasound in Conjunction With Radiation Therapy for the… | N/A | withdrawn | Jun 6, 2019 | Washington University School of Medicine | PI decided not to go forward with study. | Other (stated, no rule matched) |
| NCT04611139 | Pilot Trial of SP-2577 Plus Pembrolizumab in Select Gynecologic Cancers | Phase 1 | withdrawn | Nov 2, 2020 | HonorHealth Research Institute | Salarius discontinued support | Other (stated, no rule matched) |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Feb 10, 2025source: clinicaltrials